Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes.

Su Y, Zhang S, Wu Z, Liu W, Chen J, Deng F, Chen F, Zhu D, Hou K

Frontiers in endocrinology23 Jan 2023Cited by 5 (Europe PMC)

PMID36755915PMCIDPMC9899911DOI10.3389/fendo.2023.1054946PepBankPUB-36755915

Summary

AimTo evaluate the treatment effect Fand pharmacoeconomic value of Dugaglutide in women with type 2 diabetes.MethodsWomen (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups. The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks. The blood glucose levels, biochemical index, insulin resistance index (HOMA-IR), cost-effect ratio (CER), and drug safety were determined and compared between the two groups.ResultsBlood glucose levels, the biochemical index, and HOMA-IR were lower in both groups after the treatment (P < 0.05), and there was no statistical difference in the blood glucose levels, biochemical index and HOMA-IR between the two groups (P > 0.05). The CER levels did not differ statistically between the two groups (P > 0.05). Both the cost and the incidence of drug side effects during solution injection were lower in the observation group than in the control group after 24 weeks of treatment (P < 0.05).ConclusionBoth Dulaglutide and Liraglutide can reduce blood glucose levels, improve biochemical index, and HOMA-IR levels in women with type 2 diabetes. Dulaglutide is more cost-effective and safe.Clinical trial registrationhttps://www.chictr.org.cn/index.aspx, identifier ChiCTR1900026514.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with type 2 diabetes, blood glucose levels did not differ significantly between liraglutide and dulaglutide.
In plain wordsIn women with type 2 diabetes, blood sugar did not differ significantly between liraglutide and dulaglutide.
Peptide
Liraglutide
Outcome
No significant changeBlood glucose, difference between liraglutide and dulaglutide
Study
n = 96
Comparator
Dulaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
and there was no statistical difference in the blood glucose levels, biochemical index and HOMA-IR between the two groups
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591504
02HumanRandomized controlled trialEfficacy outcome
In women with type 2 diabetes, the biochemical index did not differ significantly between liraglutide and dulaglutide.
In plain wordsIn women with type 2 diabetes, biochemical measures did not differ significantly between liraglutide and dulaglutide.
Peptide
Liraglutide
Outcome
No significant changeBiochemical index, difference between liraglutide and dulaglutide
Study
n = 96
Comparator
Dulaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
and there was no statistical difference in the blood glucose levels, biochemical index and HOMA-IR between the two groups
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591505
03HumanRandomized controlled trialEfficacy outcome
In women with type 2 diabetes, HOMA-IR did not differ significantly between liraglutide and dulaglutide.
In plain wordsIn women with type 2 diabetes, insulin resistance did not differ significantly between liraglutide and dulaglutide.
Peptide
Liraglutide
Outcome
No significant changeHOMA-IR, difference between liraglutide and dulaglutide
Study
n = 96
Comparator
Dulaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
and there was no statistical difference in the blood glucose levels, biochemical index and HOMA-IR between the two groups
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591506
04HumanRandomized controlled trialOther
In women with type 2 diabetes, the cost-effect ratio did not differ significantly between liraglutide and dulaglutide.
In plain wordsIn women with type 2 diabetes, cost-effectiveness did not differ significantly between liraglutide and dulaglutide.
Peptide
Liraglutide
Outcome
No significant changeCost-effect ratio (CER)
Study
n = 96
Comparator
Dulaglutide
Outcome group
Cost-effectiveness · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The CER levels did not differ statistically between the two groups (P > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591507
05HumanRandomized controlled trialOther
In women with type 2 diabetes, the cost of treatment was higher with liraglutide than with dulaglutide at 24 weeks.
In plain wordsIn women with type 2 diabetes, liraglutide cost more than dulaglutide.
Peptide
Liraglutide
Outcome
IncreaseCost of treatment
Study
n = 96
Comparator
Dulaglutide
Outcome group
Cost-effectiveness · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Both the cost and the incidence of drug side effects during solution injection were lower in the observation group than in the control group after 24 weeks of treatment (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591508
06HumanRandomized controlled trialSafety outcome
In women with type 2 diabetes, side effects during injection were more frequent with liraglutide than with dulaglutide at 24 weeks.
In plain wordsIn women with type 2 diabetes, side effects during injection were more common with liraglutide than with dulaglutide.
Peptide
Liraglutide
Outcome
IncreaseIncidence of drug side effects during injection
Study
n = 96
Comparator
Dulaglutide
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Both the cost and the incidence of drug side effects during solution injection were lower in the observation group than in the control group after 24 weeks of treatment (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591509
07HumanRandomized controlled trialEfficacy outcome
In women with type 2 diabetes, blood glucose did not differ significantly between dulaglutide and liraglutide.
In plain wordsIn women with diabetes, blood sugar did not differ significantly between dulaglutide and liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBlood glucose
Study
n = 96
Comparator
Liraglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Blood glucose levels, the biochemical index, and HOMA-IR were lower in both groups after the treatment (P P > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591510
08HumanRandomized controlled trialEfficacy outcome
In women with type 2 diabetes, the biochemical index did not differ significantly between dulaglutide and liraglutide.
In plain wordsIn women with diabetes, the biochemical index did not differ significantly between dulaglutide and liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBiochemical index
Study
n = 96
Comparator
Liraglutide
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Blood glucose levels, the biochemical index, and HOMA-IR were lower in both groups after the treatment (P P > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591511
09HumanRandomized controlled trialEfficacy outcome
In women with type 2 diabetes, HOMA-IR did not differ significantly between dulaglutide and liraglutide.
In plain wordsIn women with diabetes, insulin resistance did not differ significantly between dulaglutide and liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHOMA-IR
Study
n = 96
Comparator
Liraglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Blood glucose levels, the biochemical index, and HOMA-IR were lower in both groups after the treatment (P P > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591512
10HumanRandomized controlled trialOther
In women with type 2 diabetes, cost-effect ratios did not differ significantly between dulaglutide and liraglutide.
In plain wordsIn women with diabetes, cost-effect ratios did not differ significantly between dulaglutide and liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeCost-effect ratio
Study
n = 96
Comparator
Liraglutide
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The CER levels did not differ statistically between the two groups (P > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591513
11HumanRandomized controlled trialOther
In women with type 2 diabetes, treatment cost was lower with dulaglutide than liraglutide.
In plain wordsIn women with diabetes, treatment cost was lower with dulaglutide than liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTreatment cost
Study
n = 96
Comparator
Liraglutide
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Both the cost and the incidence of drug side effects during solution injection were lower in the observation group than in the control group after 24 weeks of treatment (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591514
12HumanRandomized controlled trialSafety outcome
In women with type 2 diabetes, injection-associated drug side effects were less frequent with dulaglutide than liraglutide.
In plain wordsIn women with diabetes, injection-associated side effects were less frequent with dulaglutide than liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDrug side effects during injection
Study
n = 96
Comparator
Liraglutide
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Both the cost and the incidence of drug side effects during solution injection were lower in the observation group than in the control group after 24 weeks of treatment (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591515
13HumanRandomized controlled trialEfficacy outcome
In women with type 2 diabetes, blood glucose levels were lower after 24 weeks of liraglutide.
In plain wordsIn women with type 2 diabetes, blood sugar was lower after treatment with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseBlood glucose levels after treatment
Study
n = 48
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Blood glucose levels, the biochemical index, and HOMA-IR were lower in both groups after the treatment
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591501
14HumanRandomized controlled trialEfficacy outcome
In women with type 2 diabetes, the biochemical index was lower after 24 weeks of liraglutide.
In plain wordsIn women with type 2 diabetes, biochemical measures were lower after treatment with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseBiochemical index after treatment
Study
n = 48
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Blood glucose levels, the biochemical index, and HOMA-IR were lower in both groups after the treatment
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591502
15HumanRandomized controlled trialEfficacy outcome
In women with type 2 diabetes, insulin resistance (HOMA-IR) was lower after 24 weeks of liraglutide.
In plain wordsIn women with type 2 diabetes, insulin resistance was lower after treatment with liraglutide.
Peptide
Liraglutide
Outcome
DecreaseHOMA-IR after treatment
Study
n = 48
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Blood glucose levels, the biochemical index, and HOMA-IR were lower in both groups after the treatment
2 context sentences(design, population, supporting numbers)
Summary · context
Women (n=96) with type 2 diabetes recruited from June 2019 to December 2021 were randomized into two equal groups.
Summary · context
The control group was treated with Liraglutide, and the observation group was treated with Dulaglutide, both for 24 weeks.
Show in the study text Report a problemFND-3675591503

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes.

Summary

Results from this study15

Version history

Subjects

Publication types

MeSH terms

Keywords